The Dime

Who Benefits From Federal Cannabis Limbo? ft. Jay Rosenthal

Episode Summary

Federal cannabis reform is supposed to open the same door for everyone. The current market says otherwise. The largest operators do not share one political agenda, and some of the barriers they complain about are also widening their moats. As capital markets, international medical standards, and state regulation collide, the operators built for uncertainty may be the ones hardest to dislodge. This week we sit down with Jay Rosenthal • Limbo as a moat • EU GMP advantage • Regulation's hidden winners

Episode Notes

Federal cannabis reform is supposed to open the same door for everyone. The current market says otherwise.

The largest operators do not share one political agenda, and some of the barriers they complain about are also widening their moats. As capital markets, international medical standards, and state regulation collide, the operators built for uncertainty may be the ones hardest to dislodge.

This week we sit down with Jay Rosenthal

Chapters

Guest Links

Our Links

Follow The Dime for more conversations on cannabis business, operations, and international markets.

Share this episode with an operator rethinking their edibles.